2021

1. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

   Multiple Sclerosis and Related Disorders, Vol. 47

2. Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD

   Annals of Neurology, Vol. 89, Núm. 6, pp. 1088-1098